WO2001056551A3 - Method and formulation for treatment of vasoconstriction - Google Patents

Method and formulation for treatment of vasoconstriction Download PDF

Info

Publication number
WO2001056551A3
WO2001056551A3 PCT/CH2001/000062 CH0100062W WO0156551A3 WO 2001056551 A3 WO2001056551 A3 WO 2001056551A3 CH 0100062 W CH0100062 W CH 0100062W WO 0156551 A3 WO0156551 A3 WO 0156551A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasoconstriction
formulation
treatment
method
compositions
Prior art date
Application number
PCT/CH2001/000062
Other languages
French (fr)
Other versions
WO2001056551A2 (en
Inventor
Ralph A Schmid
Gabriele Schoedon
Original Assignee
Ralph A Schmid
Gabriele Schoedon
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SE0000307-9 priority Critical
Priority to SE0000307A priority patent/SE0000307D0/en
Application filed by Ralph A Schmid, Gabriele Schoedon, Univ Zuerich filed Critical Ralph A Schmid
Publication of WO2001056551A2 publication Critical patent/WO2001056551A2/en
Publication of WO2001056551A3 publication Critical patent/WO2001056551A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Compositions and methods useful for achieving therapeutic effects such as the prevention of vasoconstriction and improvement of the preservation and survival of a transplanted organ. More specifically, the compositions exhibit synergy and comprise amounts of two therapeutic agents selected from the group consisting of BH4 and its precursors , on the one hand and membrane permeable cGMP analogues on the other.
PCT/CH2001/000062 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction WO2001056551A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0000307-9 2000-01-31
SE0000307A SE0000307D0 (en) 2000-01-31 2000-01-31 Method and formulation for the treatment of vasoconstriction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2660901A AU2660901A (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction

Publications (2)

Publication Number Publication Date
WO2001056551A2 WO2001056551A2 (en) 2001-08-09
WO2001056551A3 true WO2001056551A3 (en) 2002-07-11

Family

ID=20278294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2001/000062 WO2001056551A2 (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction

Country Status (3)

Country Link
AU (1) AU2660901A (en)
SE (1) SE0000307D0 (en)
WO (1) WO2001056551A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
BRPI0416105A (en) * 2003-10-31 2007-01-02 Altana Pharma Ag use of BH4 for the treatment of respiratory disease
ES2596827T3 (en) 2003-11-17 2017-01-12 Biomarin Pharmaceutical Inc. Treatment of phenylketonuria with BH4
EP1940392A2 (en) * 2005-05-11 2008-07-09 Nycomed GmbH Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative
EP1965803A1 (en) * 2005-12-05 2008-09-10 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. G. C. VAN AMSTERDAM ET AL.: "Tetrahydrobiopterin induces vasodilatation via enhancement of cGMP level", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 215, 1992, pages 349 - 350, XP001007204 *
R.A. SCHMID, S. HILLINGER ET AL.: "The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 118, no. 4, October 1999 (1999-10-01), pages 726 - 732, XP001007207 *
S. HILLINGER ET AL.: "New strategies to reduce ischemia/reperfusion of the NO/cGMP pathway", CHIR. FORUM EXP. KLIN. FORSCH., 1999, pages 723 - 728, XP001007191 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Also Published As

Publication number Publication date
SE0000307D0 (en) 2000-01-31
WO2001056551A2 (en) 2001-08-09
AU2660901A (en) 2001-08-14

Similar Documents

Publication Publication Date Title
TW510788B (en) Surgical stabilizer devices and methods
CA2379948C (en) Beta-carboline pharmaceutical compositions
ZA200104998B (en) Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors.
WO2001068609B1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2002092028A3 (en) Oral care compositions
NZ511643A (en) Controlled release galantamine composition
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
WO2004045537A3 (en) Edible film for relief of cough or symptoms associated with pharyngitis
TW200724033A (en) Anthranilamide arthropodicide treatment
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MXPA05000328A (en) Inhibitors of tyrosine kinases.
MXPA06002394A (en) Use of modified cyclosporins for the treatment of hcv disorders.
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
MXPA01005641A (en) Cancer treatment composition and method using natural plant essential oils.
WO2009074735A8 (en) Use of a novel natural agent in cosmetic compositions
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO2003051294A3 (en) Mitocidal compositions and methods
HU0100801A2 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intented to reduce hyperglycaemia
WO2001081346A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
NZ529205A (en) Substituted azaindoles as inhibitors of protein kinases, and process for their preparation
ZA200306329B (en) Treated plant seeds with controlled release of active agents.
NZ510275A (en) Controlled-release pharmaceutical formulations containing a CGMP PDE-5 inhibitor
CA2494340A1 (en) Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
WO2000007979A3 (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP